Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Muscarinic Acetylcholine Receptor M4 (CHRM4) - Overview
Muscarinic Acetylcholine Receptor M4 (CHRM4) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Muscarinic Acetylcholine Receptor M4 (CHRM4) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Muscarinic Acetylcholine Receptor M4 (CHRM4) - Companies Involved in Therapeutics Development
Addex Therapeutics Ltd
Avex Life Sciences Corp
AstraZeneca Plc
Cerevel Therapeutics Holdings Inc
Karu Therapeutics Inc
Lan Sheng Biomedicine Suzhou Co Ltd
Lenz Therapeutics LLC
MapLight therapeutics Inc
Neumora Therapeutics Inc
Neurocrine Biosciences Inc
NeuroSolis Inc
Sosei Group Corp
Suven Life Sciences Ltd
Muscarinic Acetylcholine Receptor M4 (CHRM4) - Drug Profiles
(aceclidine + tropicamide) - Drug Profile
(trospium chloride + xanomeline) - Drug Profile
blarcamesine hydrochloride - Drug Profile
emraclidine - Drug Profile
HTL-0016878 - Drug Profile
Lead Optimization - Drug Profile
LS-001 - Drug Profile
M4 PAMs for Schizophrenia and Other Psychosis - Drug Profile
ML-007 - Drug Profile
NMRA-M4R - Drug Profile
NSX-0527 - Drug Profile
NSX-0527f - Drug Profile
NSX-0559 - Drug Profile
NSX-0559f - Drug Profile
Small Molecule to Agonize Muscarinic Acetylcholine Receptor M4 for Schizophrenia - Drug Profile
Small Molecule to Agonize Muscarinic M1 and M4 Receptors for Unspecified Neurologic Diseases - Drug Profile
Small Molecules to Agonize Muscarinic Acetylcholine Receptor 4 for Psychosis - Drug Profile
VU-0467154 - Drug Profile
VU-6000918 - Drug Profile
VU-6001852 - Drug Profile
Muscarinic Acetylcholine Receptor M4 (CHRM4) - Dormant Products
Muscarinic Acetylcholine Receptor M4 (CHRM4) - Discontinued Products
Muscarinic Acetylcholine Receptor M4 (CHRM4) - Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures

List of Figures
Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Top 10 Indications, 2022
Number of Products by Mechanism of Actions, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Routes of Administration, 2022
Number of Products by Stage and Routes of Administration, 2022
Number of Products by Stage and Routes of Administration, 2022

List of Tables

List of Tables
Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Indication, 2022
Number of Products under Development by Companies, 2022
Products under Development by Companies, 2022
Products under Development by Companies, 2022 (Contd..1)
Products under Development by Companies, 2022 (Contd..2)
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Pipeline by Addex Therapeutics Ltd, 2022
Pipeline by Anavex Life Sciences Corp, 2022
Pipeline by AstraZeneca Plc, 2022
Pipeline by Cerevel Therapeutics Holdings Inc, 2022
Pipeline by Karuna Therapeutics Inc, 2022
Pipeline by Lan Sheng Biomedicine Suzhou Co Ltd, 2022
Pipeline by Lenz Therapeutics LLC, 2022
Pipeline by MapLight therapeutics Inc, 2022
Pipeline by Neumora Therapeutics Inc, 2022
Pipeline by Neurocrine Biosciences Inc, 2022
Pipeline by NeuroSolis Inc, 2022
Pipeline by Sosei Group Corp, 2022
Pipeline by Suven Life Sciences Ltd, 2022
Dormant Products, 2022
Discontinued Products, 2022